Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition 
Dollar Slips as Risk Appetite Grows Amid Nvidia Rally and Iran Peace Hopes 
Asian Stocks Rally as Nvidia Earnings Boost Tech Shares, Samsung Jumps on Wage Deal 
US Economy Fueled by AI Investment Faces Rising Risks Ahead of Fed Meeting 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Marco Rubio Visits India to Rebuild U.S.-India Ties Amid Trade and Geopolitical Tensions 
PDG Explores $1 Billion Sale of China Data Center Assets 
Spying, Southampton and economic pressure cooker of the ‘richest match in football’ 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Google Expands AI Partnership With Singapore Government 
Japan Manufacturing Growth Slows in May as Services Sector Stagnates Amid Rising Middle East Supply Costs 
Walmart Stock Falls Despite Strong Q1 Revenue Beat and E-Commerce Growth 
Trump to Swear In Kevin Warsh as New Federal Reserve Chair Amid Inflation Concerns 
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
SpaceX Eyes AI Computing Expansion Ahead of Historic IPO 
Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
